Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 21cabozantinib 12Specimen Handling 11Ipilimumab 10belzutifan 9pembrolizumab 8Magnetic Resonance Spectroscopy 8CTLA-4 Antigen 5Biopsy 5Axitinib 5lenvatinib 4Sunitinib 4Immunoglobulin G 3Disulfides 3zimberelimab 2tivozanib 2relatlimab 2pazopanib 2palbociclib 2atezolizumab 2aldesleukin 2X-Rays 2Watchful Waiting 2Radiosurgery 2Nephrectomy 2Bevacizumab 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × balstilimab × 30 days × Clear all
NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
16 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡